期刊文献+

卡培他滨维持治疗老年晚期转移性结直肠癌的效果观察 被引量:2

下载PDF
导出
摘要 目的研究卡培他滨维持治疗老年晚期转移性结直肠癌的临床效果。方法选取2012年6月至2014年8月漯河市第六人民医院收治的老年晚期转移性结直肠癌患者120例,随机分为观察组和对照组,各60例,给予观察组患者卡培他滨维持治疗,对照组患者不进行维持治疗,连续应用2个周期后评价两组患者治疗效果及不良反应发生情况。结果观察组患者有效率显著高于对照组,不良反应发生率高于对照组(P<0.05),但不良反应经对症处理后均缓解,未影响治疗。结论对老年晚期结直肠癌患者进行以氟尿嘧啶类为主的联合化疗后再采用卡培他滨维持治疗,可有效提高患者耐受性及生活质量,且安全性较高。
作者 陈红娜
出处 《河南医学研究》 CAS 2016年第4期679-679,共1页 Henan Medical Research
  • 相关文献

参考文献3

二级参考文献18

  • 1沈琳,马冬.晚期结直肠癌使用FOLFOX4或奥沙利铂断断-续续模式的FOLFOX7(OPTIMOX1)的随机临床研究[J].循证医学,2006,6(5):259-262. 被引量:47
  • 2张弘纲,李进,秦叔逵,张燕军,宋恕平,储大同.国产伊立替康加5-氟尿嘧啶加亚叶酸钙联合沙利度胺治疗晚期大肠癌的随机对照研究[J].中华肿瘤杂志,2007,29(3):228-231. 被引量:16
  • 3De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].J Clin Oncol, 2000,18 (16) : 2938-2947.
  • 4Sanoff H K, Sargent D J, Campbell M Data and Prognostic Factor Analysis Irinotecan Combinations for Advanced N9741 [J]. J Clin Oncol, 2008,26(35) E, et al. Five-Year of Oxaliplatin and Colorectal Cancer: 5721-5727.
  • 5Cheeseman S L, Joel S P, Chester J D, et al. A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer [ J ]. Br J Cancer, 2002,87 (4) : 393-399.
  • 6Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [J]. J Clin Oncol, 2005, 23 (36) : 9441-9442.
  • 7Novello S, Bruzzi P, Barone C. Phase 111 study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol [J]. 2007,18(5) :903-908.
  • 8Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Finalresuhs of OPTIMOX2, a large randomized phase ]I study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study [J]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2007,25(18S) :4013.
  • 9Chibaudel B, Maindrauh-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study [J].J Clin Oncol, 2009,27 (34) : 5727-5733.
  • 10Tournigand C, Samson B, Scheithauer W, et al. Bevacizumab (Bey) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bey, in patients (pts) with metastatic colorectal cancer (mCRC) : Efficacy and safety results of the International GERCORDREAM phase 111 trial [J]. J Clin Oncol, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2012,30 (18S) : LBA3500.

共引文献62

同被引文献17

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部